

# SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>EL SALVADOR</b>	2. DATE OF BIRTH			2a. AGE <b>37 Years</b>	3. SEX <b>Female</b>	3a. WEIGHT <b>Unk</b>	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION  <input type="checkbox"/> PATIENT DIED  <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION  <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  <input type="checkbox"/> LIFE THREATENING
		Day	Month	Year				Day	Month	Year	
			<b>PRIVACY</b>						<b>JUN</b>	<b>2025</b>	

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)  
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)  
**Very sleepy the day after the application [Somnolence]  
High fatigue the day after application [Fatigue]**

Case Description: Patient Demographics: 37 Years old Female

Event(s): Very sleepy the day after the application, High fatigue the day after application

Suspect Product(s) (Name, IFU): trulicity 1.5mg (dulaglutide) for treatment of DM2

(Continued on Additional Information Page)

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) <b>#1 ) Trulicity 1.5mg (Dulaglutide) Solution for injection in pre-filled pen, 1.5 mg</b>		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) <b>#1 ) 1.5 mg, weekly (1/W)</b>	16. ROUTE(S) OF ADMINISTRATION <b>#1 ) Subcutaneous</b>	
17. INDICATION(S) FOR USE <b>#1 ) DM2 (Type 2 diabetes mellitus)</b>		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) <b>#1 ) JUN-2025 / Ongoing</b>	19. THERAPY DURATION <b>#1 ) Unknown</b>	

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates <b>Unknown to Ongoing</b>	Type of History / Notes <b>Medical Condition</b>	Description <b>Type 2 diabetes mellitus (Type 2 diabetes mellitus)</b>

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER <b>Eli Lilly &amp; Company</b>		26. REMARKS
	24b. MFR CONTROL NO. <b>SV202507006710</b>	
24c. DATE RECEIVED BY MANUFACTURER <b>03-JUL-2025</b>	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input checked="" type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous	
DATE OF THIS REPORT <b>09-JUL-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

25b. NAME AND ADDRESS OF REPORTER  
**NAME AND ADDRESS WITHHELD.**

NAME AND ADDRESS WITHHELD.

09-Jul-2025 08:51

---

**ADDITIONAL INFORMATION**

**7+13. DESCRIBE REACTION(S) continued**

Action(s) Taken: trulicity 1.5mg (dulaglutide) - No Change

Event Outcome(s): Very sleepy the day after the application (Unknown), High fatigue the day after application (Unknown)

Reporter's Opinion of Relatedness: trulicity 1.5mg (dulaglutide) - Very sleepy the day after the application (Yes) , High fatigue the day after application (Yes)